Tocilizumab in severe COVID-19 – A randomized, double-blind, placebo-controlled trial

Tocilizumab in severe COVID-19 – A randomized, double-blind, placebo-controlled trial

Background: The therapeutic effectiveness of interleukin-6 receptor inhibitor in critically ill hospitalized patients with coronavirus disease 2019 (COVID-19) is uncertain. Methods: To evaluate the efficacy and safety of the outcome as recovery or death of tocilizumab for severe acute respiratory sy...

Full description

Bibliographic Details
Main Authors: Muhammad Irfan Malik, Sardar Al Fareed Zafar, Fabiha Qayyum, Muna Malik, Muhammad Sohaib Asghar, Muhammad Junaid Tahir, Ammarah Arshad, Fatima Khalil, Hafiza Shafia Naz, Mudassar Aslam, Jodat Saleem, Abdul Aziz, Mustafa Usman Azhar, Muhammad Naqash, Zohaib Yousaf
Format: Article
Language:English
Published: Elsevier 2022-06-01
Series:Infectious Medicine
Subjects:
Inflammatory
Infectious
Immunosuppression
COVID-19
Therapy
Trial
Online Access:http://www.sciencedirect.com/science/article/pii/S2772431X22000193

Internet

http://www.sciencedirect.com/science/article/pii/S2772431X22000193

Similar Items